CN107249621A - 用于治疗肺结节病的粘液溶解剂 - Google Patents

用于治疗肺结节病的粘液溶解剂 Download PDF

Info

Publication number
CN107249621A
CN107249621A CN201580060653.1A CN201580060653A CN107249621A CN 107249621 A CN107249621 A CN 107249621A CN 201580060653 A CN201580060653 A CN 201580060653A CN 107249621 A CN107249621 A CN 107249621A
Authority
CN
China
Prior art keywords
patient
dnase
lung
sarcoidosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580060653.1A
Other languages
English (en)
Chinese (zh)
Inventor
巴里·伯恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gotham Biopharmaceuticals Inc
Original Assignee
Gotham Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gotham Biopharmaceuticals Inc filed Critical Gotham Biopharmaceuticals Inc
Publication of CN107249621A publication Critical patent/CN107249621A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201580060653.1A 2014-09-08 2015-09-04 用于治疗肺结节病的粘液溶解剂 Pending CN107249621A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462047361P 2014-09-08 2014-09-08
US62/047,361 2014-09-08
PCT/US2015/048606 WO2016040169A2 (en) 2014-09-08 2015-09-04 Methods of treating pulmonary sarcoidosis

Publications (1)

Publication Number Publication Date
CN107249621A true CN107249621A (zh) 2017-10-13

Family

ID=54697634

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580060653.1A Pending CN107249621A (zh) 2014-09-08 2015-09-04 用于治疗肺结节病的粘液溶解剂

Country Status (11)

Country Link
US (2) US9402884B2 (https=)
EP (1) EP3191090A2 (https=)
JP (1) JP2017527618A (https=)
KR (1) KR20170045750A (https=)
CN (1) CN107249621A (https=)
AU (1) AU2015315455A1 (https=)
BR (1) BR112017004533A2 (https=)
CA (1) CA2960622A1 (https=)
IL (1) IL250980A0 (https=)
MX (1) MX2017002948A (https=)
WO (1) WO2016040169A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP3668972B8 (en) 2017-08-18 2024-11-13 Neutrolis, Inc. Engineered dnase enzymes and use in therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
AU2019358915B2 (en) 2018-10-08 2025-09-18 Neutrolis, Inc. Engineering of DNASE enzymes for manufacturing and therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
CN113613638A (zh) * 2019-02-22 2021-11-05 希拉治疗公司 可吸入治疗剂
WO2024197201A1 (en) * 2023-03-22 2024-09-26 The Regents Of The University Of California Systems and methods for the quantitative assessment of airway mucus plug pathology

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
JP2007230919A (ja) * 2006-03-01 2007-09-13 Ki Pharma Kk 美白剤
CN103648488A (zh) * 2011-07-05 2014-03-19 比蔻匹亚有限公司 药物组合物和在治疗咳嗽病况中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004302A3 (en) 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
JP5264904B2 (ja) * 2007-08-03 2013-08-14 ユセベ ファルマ ソシエテ アノニム スルファニル誘導体、及び合成中間体としてのその使用
ES2399179T3 (es) * 2008-08-07 2013-03-26 Pulmagen Therapeutics (Inflammation) Limited Tratamiento de enfermedad respiratoria
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
GB201002224D0 (en) * 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
JP2007230919A (ja) * 2006-03-01 2007-09-13 Ki Pharma Kk 美白剤
CN103648488A (zh) * 2011-07-05 2014-03-19 比蔻匹亚有限公司 药物组合物和在治疗咳嗽病况中的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ERNST RIETSCHEL等: "Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE》 *
SHAK S.: "重组人DNasel气雾剂治疗肺囊性纤维化", 《国外医药--合成药、生化药、制剂分册》 *
姚其正等: "《药物合成反应》", 30 September 2012, 中国医药科技出版社 *
王海生等: "《临床新药手册》", 30 September 2000, 天津科学技术出版社 *

Also Published As

Publication number Publication date
KR20170045750A (ko) 2017-04-27
CA2960622A1 (en) 2016-03-17
WO2016040169A2 (en) 2016-03-17
JP2017527618A (ja) 2017-09-21
BR112017004533A2 (pt) 2018-05-08
MX2017002948A (es) 2017-08-15
US20160067317A1 (en) 2016-03-10
US9402884B2 (en) 2016-08-02
EP3191090A2 (en) 2017-07-19
AU2015315455A1 (en) 2017-04-27
IL250980A0 (en) 2017-04-30
US20170368150A1 (en) 2017-12-28
WO2016040169A3 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
US9402884B2 (en) Methods of treating pulmonary sarcoidosis
Mainz et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis—results of a multicenter, prospective, randomized, double-blind, controlled trial
AU2014249531B2 (en) Use of levocetirizine and montelukast in the treatment of traumatic injury
Reid Osteoporosis treatment: focus on safety
Parr et al. Natural history and quality of life in patients with cystine urolithiasis: a single centre study
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
Casale et al. Post-operative nebulized sodium hyaluronate versus spray after functional endoscopic sinus surgery for chronic rhinosinusitis
Amorós et al. Central giant cell granuloma: off-label treatment with Denosumab in a patient with Noonan syndrome
Oz et al. Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab
Kim et al. The efficacy of cotton ball packing after endoscopic sinus surgery: a prospective, randomized, controlled trial
JEICAN et al. Rehabilitation of patients with chronic rhinosinusitis after functional endoscopic sinus surgery
Pendolino et al. The role of large cavity sinus surgery in the management of chronic rhinosinusitis in non-steroidal anti-inflammatory drug exacerbated respiratory disease: a single-centre experience and long-term outcomes
RU2499597C2 (ru) Способ лечения и профилактики назальной обструкции у больных полипозным риносинуситом
Lee et al. Eye Globe Rupture Caused by Dental Implant–Related Maxillary Sinusitis
Gandhewar et al. Mucormycosis, the Black Fungus in the Post-COVID-19 Pandemic: A Case Report with Review of Literature
Badea et al. Rhinosinusal mucormycosis: Literature review and some particular cases.
RU2830337C1 (ru) Способ лечения больных с туберкулезом легких
Deokar et al. Post COVID-19 mucormycosis (black fungus) and its prosthodontic considerations
Okutomi et al. Two Cases of Alport Syndrome with COVID-19
Ravichandran et al. Management of PostCovid-19 RhinoMaxillary Mucormycotic Osteomyelitis–A review with a report of a typical case.
Meliante et al. Dupixent's Efficacy in Cystic Fibrosis Related Chronic Rhinosinusitis With Nasal Polyposis: A Pilot Study
Manker et al. Surgical management of oro-antral fistula post-medication related osteonecrosis of maxilla: A case report
INTERSTITIAL Weight loss, fatigue, and renal failure
Kalra et al. Mucormycosis: A case report
Mauceri et al. Oral manifestations in patients affected by psoriasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171013

WD01 Invention patent application deemed withdrawn after publication